Immunotherapy in NMSCs

CE / CME

Immunotherapy Advances in the Management of Nonmelanoma Skin Cancers

Pharmacists: 1.00 contact hour (0.1 CEUs)

Physicians: Maximum of 1.00 AMA PRA Category 1 Credit

Released: May 09, 2023

Expiration: May 08, 2024

Zeynep Eroglu
Zeynep Eroglu, MD
Bethany Withycombe
Bethany Withycombe, PharmD, BCOP

Activity

Progress
1
Course Completed

References

  1. Kim DP, Kus KJB, Ruiz E. Basal cell carcinoma review. Hematol Oncol Clin North Am. 2019;33:13-24.
  2. Heath MS, Bar A. Basal cell carcinoma. Dermatol Clin. 2023;41:13-21.
  3. Sekulic A, Migden MR, Basset-Seguin N, et al. Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: final update of the pivotal ERIVANCE BCC study. BMC Cancer. 2017;17:332.
  4. Sekulic A, Yoo S, Kudchadkar R, et al. Real-world assessment and treatment of locally advanced basal cell carcinoma: findings from the RegiSONIC disease registry. PLoS One. 2022;17:e0262151.
  5. Basset-Séguin N, Hauschild A, Kunstfeld R, et al. Vismodegib in patients with advanced basal cell carcinoma: primary analysis of STEVIE, an international, open-label trial. Eur J Cancer. 2017;86:334-348.
  6. Dummer R, Guminksi A, Gutzmer R, et al. Long-term efficacy and safety of sonidegib in patients with advanced basal cell carcinoma: 42-month analysis of the phase II randomized, double-blind BOLT study. Br J Dermatol. 2020;182:1369-1378.
  7. Goodman AM, Kato S, Cohen PR, et al. Genomic landscape of advanced basal cell carcinoma: implications for precision treatment with targeted and immune therapies. Oncoimmunology. 2018; 7:e1404217.
  8. Stratigos AJ, Sekulic A, Peris K, et al. Cemiplimab in locally advanced basal cell carcinoma after hedgehog inhibitor therapy: an open-label, multi-centre, single-arm, phase 2 trial. Lancet Oncol. 2021;22:848-857.
  9. Stratigos AJ, Sekulic A, Peris K, et al. Phase 2 study of cemiplimab in patients with locally advanced basal cell carcinoma after hedgehog inhibitor therapy: long-term follow-up. Presented at: 18th European Association of DermatoOncology Congress; April 21-23, 2022. Abstract 29.
  10. Cemiplimab [prescribing information]. Tarrytown, NY: Regeneron Pharmaceuticals; 2022.
  11. Lewis DJ, Sobanko JF, Etzkorn JR, et al. Merkel cell carcinoma. Dermatol Clin. 2023;41:101-115.
  12. Boerlin A, Ramelyte E, Maul J, et al. Efficacy and tolerability of anti-PD1 antibody in combination with pulsed hedgehog inhibitor in advanced basal cell carcinoma. Ann Oncol. 2021;32:S867-S905.
  13. Schenk KM, Deutsch JS, Schollenberger MD, et al. Nivolumab (NIVO) +/- relatlimab (RELA) or ipilimumab (IPI) for patients (pts) with advanced treatment-naive or -refractory basal cell carcinoma (BCC). Presented at: ESMO Congress; September 9-13, 2022. Abstract 820P.
  14. Chong CY, Goh MS, Porceddu SV, et al. The current treatment landscape of cutaneous squamous cell carcinoma. Am J Clin Dermatol. 2023;24:25-40.
  15. Pembrolizumab [prescribing information]. Rahway, NJ: Merck Sharp & Dohme; 2023.
  16. Migden MR, Schmults C, Khushanlani N, et al. Phase II study of cemiplimab in patients with advanced cutaneous squamous cell carcinoma (CSCC): final analysis from EMPOWER-CSCC-1 groups 1, 2 and 3. Presented at: ESMO Congress; September 9-13, 2022. Abstract 814P.
  17. Hughes BGM, Munoz-Couselo E, Mortier L, et al. Pembrolizumab for locally advanced and recurrent/metastatic cutaneous squamous cell carcinoma (KEYNOTE-629 study): an open-label, nonrandomized, multicenter, phase II trial. Ann Oncol. 2021;32:1276-1285.
  18. Maubec E, Petrow P, Scheer-Senyarich I, et al. Phase II study of cetuximab as first-line single-drug therapy in patients with unresectable squamous cell carcinoma of the skin. J Clin Oncol. 2011;29:3419-3426.
  19. Kumar V, Shinagare AB, Rennke HG, et al. The safety and efficacy of checkpoint inhibitors in transplant recipients: a case series and systematic review of literature. Oncologist. 2020;25:505-514.
  20. Schenk KH, Stein JE, Chandra S, et al. Nivolumab (NIVO) + tacrolimus (TACRO) + prednisone (PRED) +/- ipilimumab (IPI) for kidney transplant recipients (KTR) with advanced cutaneous cancers. Presented at: American Society of Clinical Oncology Annual Meeting; June 3-7, 2022. Abstract 9507.
  21. Milhem MM, Vanderwalde AM, Bowles TL, et al. Updated results from the skin cancer cohorts from an ongoing phase 1/2 multicohort study of RP1, an enhanced potency oncolytic HSV, combined with nivolumab (IGNYTE). Presented at: American Society of Clinical Oncology Annual Meeting; June 3-7, 2022. Abstract 9553.
  22. Gross ND, Miller DM, Khushalani NI, et al. Neoadjuvant cemiplimab for stage II-IV cutaneous squamous cell carcinoma. Presented at: ESMO Congress; September 9-13, 2022. Abstract 789O.
  23. Gross ND, Miller DM, Khushalani NI, et al. Neoadjuvant cemiplimab for stage II-IV cutaneous squamous cell carcinoma. N Engl J Med. 2022;387:1557-1568.
  24. Haydon AM, Khushalani NI, Robert C, et al. A randomized, controlled, open-label, phase 2 study of cemiplimab ± RP1 in patients with advanced cutaneous squamous cell carcinoma (CERPASS). Presented at: American Society of Clinical Oncology Annual Meeting; June 3-7, 2022. Abstract TPS9593.
  25. Rischin D, Brungs D, Day F, et al. C-POST protocol update: a phase 3, randomized, double-blind study of adjuvant cemiplimab versus placebo post-surgery and radiation therapy (RT) in patients (pts) with high-risk cutaneous squamous cell carcinoma (cSCC). Presented at: American Society of Clinical Oncology Annual Meeting; June 3-7, 2022. Abstract TPS9592.
  26. Avelumab [prescribing information]. Rockland, MA: EMD Serono; 2022.
  27. Retifanlimab [prescribing information]. Wilmington, DE. Incyte Corporation; 2023.
  28. D’Angelo SP, Bhatia S, Brohl AS, et al. Avelumab in patients with previously treated metastatic Merkel cell carcinoma: long-term data and biomarker analyses from the single-arm phase 2 JAVELIN Merkel 200 trial. J Immunother Cancer. 2020;8:e000674. 
  29. D'Angelo SP, Lebbé C, Mortier L, et al. First-line avelumab in a cohort of 116 patients with metastatic Merkel cell carcinoma (JAVELIN Merkel 200): primary and biomarker analyses of a phase II study. J Immunother Cancer. 2021;9:e002646.
  30. D’Angelo SP, Bhatia S, Brohl AS. Avelumab in patients with previously treated metastatic Merkel cell carcinoma (JAVELIN Merkel 200): updated overall survival data after >5 years of follow-up. ESMO Open. 2021;6:100290.
  31. Nghiem P, Bhatia S, Lipson EJ, et al. Three-year survival, correlates and salvage therapies in patients receiving first-line pembrolizumab for advanced Merkel cell carcinoma. J Immunother Cancer. 2021;9:e002478.
  32. Oncology Nursing News. FDA grants accelerated approval to retifanlimab for locally advanced Merkel cell carcinoma. oncnursingnews.com/view/fda-grants-accelerated-approval-to-retifanlimab-for-locally-advanced-merkel-cell-carcinoma. Accessed April 4, 2023.
  33. Kim S, Wuthrick E, Blakaj D, et al. Combined nivolumab and ipilimumab with or without stereotactic body radiation therapy for advanced Merkel cell carcinoma: a randomised, open label, phase 2 trial. Lancet. 2022;400:1008-1019.
  34. Topalian SL, Bhatia S, Amin A, et al. Neoadjuvant nivolumab for patients with resectable Merkel cell carcinoma in the CheckMate 358 Trial. J Clin Oncol. 2020;38:2476-2487.
  35. Becker JC, Ugurel S, Leiter-Stoppke U, et al. Adjuvant immunotherapy with nivolumab (NIVO) versus observation in completely resected Merkel cell carcinoma (MCC): disease-free survival (DFS) results from ADMEC-O, a randomized, open-label phase II trial. Presented at: ESMO Congress; September 9-13, 2022. Abstract 787O.
  36. Martins F, Sofiya L, Sykiotis GP. Adverse effects of immune-checkpoint inhibitors: epidemiology, management, and surveillance. Nat Rev Clin Oncol. 2019;16:563-580.
  37. Owen CN, Bai X, Lo SN, et al. Delayed immune-related adverse events with anti-PD-1-based immunotherapy in melanoma. Ann Oncol. 2021;32:917-925.
  38. National Cancer Institute. Division of cancer treatment and diagnosis. Common terminology criteria for adverse events. v5.0. ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_8.5x11.pdf. Accessed April 4, 2023.
  39. Schneider BJ, Naidoo J, Santomasso BD, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update. J Clin Oncol. 2021;39:4073-4126.
  40. National Comprehensive Cancer Network. Management of immunotherapy-related toxicities. v.1.2022. nccn.org. Accessed April 4, 2023.